Search - tctmd.com

Displaying 21 - 40 of 167

Sort: Relevancy | Date

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

News Daily News

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

November 28, 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

November 21, 2024

MI Care Varies Across Asian Subgroups in the US

News Daily News

MI Care Varies Across Asian Subgroups in the US

Yael L. Maxwell

September 19, 2024

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

News Opinion Editor's Corner

Olympic Hearts: Screening for CVD Among Team USA’s Athletes

Michael O'Riordan

July 31, 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

News Conference News SCCT 2024

Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients

July 22, 2024

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

News Daily News

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

Michael O'Riordan

June 25, 2024

More Complications in Pregnancy Equals Higher Risk of ASCVD Mortality

News Daily News

More Complications in Pregnancy Equals Higher Risk of ASCVD Mortality

February 28, 2024

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

News Daily News

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

Michael O'Riordan

February 07, 2024

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

News Daily News

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Yael L. Maxwell

October 12, 2023

To Curb Secondary Event Risk, Go ‘Granular’ With Causes of TIA, Minor Stroke

News Daily News

To Curb Secondary Event Risk, Go ‘Granular’ With Causes of TIA, Minor Stroke

October 03, 2023

Population Screening for Coronary Plaque: Is the Evidence Enough?

News Conference News SCCT 2023

Population Screening for Coronary Plaque: Is the Evidence Enough?

July 31, 2023

With Focus on Stroke, Low-Dose Aspirin Still No Good for Primary Prevention

News Daily News

With Focus on Stroke, Low-Dose Aspirin Still No Good for Primary Prevention

July 26, 2023

Cardiac Rehab Saves Lives After CABG: Too Few Reap the Benefits

News Daily News

Cardiac Rehab Saves Lives After CABG: Too Few Reap the Benefits

July 24, 2023

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

News Daily News

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

July 18, 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

May 31, 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

May 24, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.